Osimert 80 mg (Osimertinib) Tablets

Osimertinib is an oral targeted anticancer medicine belonging to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor class. It is primarily used in the management of EGFR mutation-positive non-small cell lung cancer (NSCLC). The medicine is prescribed when specific activating EGFR mutations are identified through appropriate molecular or biomarker testing.

Osimertinib may be used in different treatment settings depending on the patient's cancer stage, mutation status, previous treatment history, and the treating oncologist's clinical judgment. It can be prescribed for eligible patients with early-stage disease after surgical removal of the tumor, as well as for locally advanced or metastatic EGFR-mutated NSCLC in appropriate clinical situations.

Therapeutic Effects

• Helps inhibit abnormal EGFR signaling involved in the growth and survival of certain cancer cells.
• May slow the progression of EGFR-mutated non-small cell lung cancer.
• Can help reduce or control tumor burden in patients whose cancer is sensitive to osimertinib.
• May be used to reduce the risk of cancer recurrence after surgery in selected patients.
• In advanced disease, it may help control cancer growth and disease-related symptoms.
• Osimertinib has activity against certain EGFR mutations associated with acquired resistance to earlier EGFR-targeted therapies, including the EGFR T790M mutation in appropriate treatment settings.
• Because it can penetrate the central nervous system, osimertinib may also have therapeutic activity against EGFR-mutated NSCLC involving the brain or other areas of the central nervous system.

Treatment response varies between individuals. Osimertinib should only be used when the relevant cancer diagnosis and molecular characteristics have been established by a qualified healthcare professional.

Active Ingredient

Osimertinib 80 mg

The active pharmaceutical ingredient is osimertinib, a third-generation, irreversible EGFR tyrosine kinase inhibitor. The 80 mg strength contains 80 mg of osimertinib as the active medicinal component.

Pharmacological Composition

Osimertinib is designed to selectively target certain mutant forms of the epidermal growth factor receptor. Its molecular activity allows it to interfere with signaling pathways that can contribute to uncontrolled cancer-cell proliferation.

Inactive Ingredients

The exact excipients may vary depending on the manufacturer and specific product formulation. These may include pharmaceutical-grade substances used to provide tablet structure, stability, coating, appearance, and appropriate drug release characteristics.

For patients with known allergies or sensitivities, the official product packaging or prescribing information should be checked for the complete list of inactive ingredients.

Dosage Strength

• Osimertinib: 80 mg per tablet
• Dosage form: Oral tablet
• Route of administration: Oral

Patients should not substitute another osimertinib strength or formulation without medical advice.

The appropriate osimertinib dose depends on the patient's diagnosis, treatment setting, overall health, previous cancer therapy, and tolerance of treatment. It should be taken strictly according to the prescription provided by the treating oncologist.

Standard Adult Dose

For many adult patients with an approved indication for osimertinib, the commonly recommended dose is:

80 mg orally once daily.

The tablet should generally be taken at approximately the same time each day to maintain consistent drug exposure.

How to Take Osimertinib

• Take the tablet orally with or without food.
• Swallow the tablet whole with water.
• Do not crush, split, or chew the tablet unless specifically instructed by a healthcare professional.
• Take the medicine at the same time each day whenever possible.
• Continue treatment for the duration recommended by the oncology specialist.
• Do not change the dose or discontinue treatment without consulting the prescribing physician.

If Swallowing Is Difficult

When swallowing the tablet is difficult, the tablet may be dispersed in a suitable non-carbonated liquid according to the official product instructions. The tablet should not be crushed into a powder. Patients should follow the specific administration method provided by their healthcare professional or product information.

Missed Dose

If a dose is missed, the patient should follow the prescribing information or healthcare professional's instructions. A missed dose should generally not be replaced by taking two doses together.

If vomiting occurs after taking osimertinib, another dose should not routinely be taken immediately unless specifically advised by the treating healthcare professional.

Important Administration Guidance

Osimertinib is a prescription oncology medicine and requires appropriate medical supervision. Regular clinical assessment may be necessary during treatment to evaluate therapeutic response, adverse effects, and potential changes in treatment requirements.

The dose may need to be interrupted, reduced, or otherwise adjusted if significant adverse reactions occur or if certain interacting medicines are being used. Such changes should be made only by the treating healthcare professional.